

May 1, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** Jim van Os, M.D.

**Role(s) in Work Group:** Member, Psychotic Disorders Work Group

**Institutional Affiliation(s):** Maastricht University

**City, State:** Maastricht, Netherlands

**Biographical Sketch:**

Jim van Os is Professor of Psychiatric Epidemiology and Chairman of the Department of Psychiatry and Neuropsychology at Maastricht University, Maastricht, The Netherlands, and Visiting Professor of Psychiatric Epidemiology at the Institute of Psychiatry, London, UK. He trained in Psychiatry at the Institute of Psychiatry and the Maudsley/Bethlem Royal Hospital in London (UK) and after his clinical training was awarded a three-year UK Medical Research Council Training Fellowship in Clinical Epidemiology at the London School of Hygiene and Tropical Medicine. He is on the editorial board of several European and US psychiatric journals such as *Acta Psychiatrica Scandinavica*, *European Psychiatry*, *Psychological Medicine*, *Schizophrenia Research*, *Schizophrenia Bulletin*, *Early Intervention in Psychiatry* and *The Journal of Mental Health*.

He is a member of the Psychotic Disorders Work Group of the DSM-V, and was co-chair of the APA DSM/ICD conference *Deconstructing Psychosis*.

He is Director of Psychiatric Services at Maastricht University Hospital and runs a service for treatment-resistant depression and first episode psychosis.

Areas of interest include the clinical, cognitive and genetic epidemiology of bipolar disorder, schizophrenia and depression, in particular the study of variation in overlapping dimensions of these disorders in the general population and the underlying cognitive factors and gene-environment interactions driving this variation. Treatment studies focus on implementation of Assertive Outreach and CBT in routine mental health settings, and aspects of patient-doctor communication. Over the period 1995-2008, his group published 300 papers on MEDLINE in leading psychiatric, psychological, epidemiological and general medical journals.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS** THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

| Non-Profit and Advocacy Organizations | Year(s) | Role |
|---------------------------------------|---------|------|
| None                                  |         |      |

The two tables below represent Dr. Van Os's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Van Os has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

|   |  |
|---|--|
| <p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p> | <p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p> |
|---|--|

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

| <b>Commercial or Other Organization</b> | <b>Year(s)</b> | <b>Key #(s)</b> |
|---|----------------|-----------------|
| Eli Lilly                               | 2005-2007      | 3, 4            |
| Johnson & Johnson                       | 2005-2007      | 3, 4            |
| Organon                                 | 2006           | 3, 4            |
| Lundbeck                                | 2005-2007      | 1               |
| GSK                                     | 2005           | 3               |
| Astra-Zeneca                            | 2005-2007      | 3,4             |
| Mondriaan Mental Health Care Services   | 2001-2007      | 3               |
| BMS                                     | 2005-2007      | 3               |
| Johnson & Johnson                       | 2005-2007      | 1               |

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

| <b>Commercial or Other Organization</b> | <b>Year(s)</b> | <b>Key #(s)</b> |
|---|----------------|-----------------|
| Eli-Lilly                               | 2008           | 3, 4            |
| Johnson & Johnson                       | 2008           | 3, 4            |
| Lundbeck                                | 2008           | 4               |
| Astra-Zeneca                            | 2008           | 3, 4            |
| The Mondriaan Group                     | 2008           | 3               |
| Organon                                 | 2008           | 3               |
| BMS                                     | 2008           | 3               |